Biotech firm Rallybio's Q3 net income $16 mln, reverses prior loss

Rallybio

06/11/2025 13:07

Overview

Rallybio reports Q3 net income of $16.0 mln, reversing a loss from last year

Company generated $20 mln from sale of interest in REV102

Cash runway extended through 2027, ensuring financial stability

Outlook

Rallybio expects to report RLYB116 study data in 4Q 2025

Company's cash runway extended through 2027

Rallybio evaluating future development of RLYB332

Result Drivers

REV102 SALE - Co generated $20 mln from sale of interest in REV102, boosting financial results

COST MANAGEMENT - Decrease in R&D expenses due to reduced development costs and workforce reduction, offset by increased spending on RLYB116

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
$16.02 mln
Q3 Income From Operations
-$6.93 mln
Q3 Operating Expenses
$7.14 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Rallybio Corp is $1.00, about 37.5% above its November 5 closing price of $0.63

Press Release: ID:nBw4WgBkZa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)